543 related articles for article (PubMed ID: 1628126)
1. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
[TBL] [Abstract][Full Text] [Related]
2. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
Just M; Berger R; Just V
Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
[TBL] [Abstract][Full Text] [Related]
5. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
6. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
8. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
[TBL] [Abstract][Full Text] [Related]
9. Combined vaccine against measles, mumps, rubella, and varicella.
Brunell PA; Novelli VM; Lipton SV; Pollock B
Pediatrics; 1988 Jun; 81(6):779-84. PubMed ID: 2835743
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of antibodies against measles, mumps and rubella in Israeli young adults.
Danon YL; Adir Y; Abend I; Zaaide Y; Green MS
Isr J Med Sci; 1992 Oct; 28(10):733-6. PubMed ID: 1399506
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
13. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
[TBL] [Abstract][Full Text] [Related]
14. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
André FE; Peetermans J
Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
[TBL] [Abstract][Full Text] [Related]
17. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
Narayan KM; Moffat MA
Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
[TBL] [Abstract][Full Text] [Related]
18. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
Ozaki K; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
Just M; Berger R; Glück R; Wegmann A
Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]